title: New technologies aiding dietary programmes for weight control: the oral glucose spray.
abstract: To determine whether the administration of small amounts of glucose through an oral spray device (GSD) facilitates weight loss in overweight/obese subjects involved in a lifestyle modification programme. We randomly assigned 56 overweight/obese subjects to either the treatment group (n = 32) or the control group (n = 24). All subjects in both groups followed a structured dietary programme of 6,280.2 kJ (1,500 kcal)/day and exercised minimum 150 min a week and were followed-up for a period of 60 days. Subjects assigned to the treatment group were asked to spray, during early symptoms of neuroglycopenia, 10 puffs by GSD. GSD is a device that delivers to the buccal mucosa 50 mg of glucose per puff. A mean weight loss of 3.5 ± 3.0 kg in GSD-treated group compared to 1.7 ± 2.1 kg in control group (p = 0.01) was observed. Significant differences regarding reduction of BMI (-1.3 ± 1.0 vs. -0.7 ± 0.8 kg/m2; p = 0.01) and waist circumference (-3.5 ± 3.2 vs. -0.9 ± 3.5 cm; p = 0.02) were also detected. A short-term use of GSD, in association with dietary restriction and exercise, is helpful in improving weight loss and in reducing waist circumference in overweight/obese subjects.
authors.affiliation: Department of Endocrinology and Diabetes, University Campus Bio-Medico of Rome, Via Alvaro del Portillo, 21, 00128, Rome, Italy, m.khazrai@unicampus.it.
authors.forename: Yeganeh Manon
authors.initials: YM
authors.lastname: Khazrai
authors.forename: Ernesto
authors.initials: E
authors.lastname: Maddaloni
authors.forename: Maria
authors.initials: M
authors.lastname: Altomare
authors.forename: Fabio
authors.initials: F
authors.lastname: Cacciapaglia
authors.forename: Paolo
authors.initials: P
authors.lastname: Pozzilli
mesh_terms: D000284:Administration, Oral; D000328:Adult; D015992:Body Mass Index; D001835:Body Weight / Q000502:physiology; D004038:Diet, Reducing; D015444:Exercise / Q000502:physiology; D005260:Female; D005500:Follow-Up Studies; D005947:Glucose / Q000008:administration & dosage* / Q000627:therapeutic use*; D006801:Humans; D008019:Life Style; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000503:physiopathology / Q000628:therapy*; D058993:Oral Sprays; D050177:Overweight / Q000503:physiopathology / Q000628:therapy*; D016896:Treatment Outcome; D055105:Waist Circumference / Q000502:physiology; D061217:Weight Reduction Programs / Q000379:methods* / Q000639:trends
chemical_list: D058993:Oral Sprays; D005947:Glucose